EGFR and cancer: Knockdown of DDOST or treatment with NGI-1 hindered the N-glycosylation of EGFR, obstructing the mechanism by which cancer cells compensate for ERK1/2 activity via EGFR, ultimately leading to lenvatinib resistance.